A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2017
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TITAN
- Sponsors Aragon Pharmaceuticals; Janssen Research & Development
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2017 Planned End Date changed from 1 Jul 2021 to 13 Jul 2022.
- 19 Oct 2016 Planned End Date changed from 1 Feb 2022 to 1 Jul 2021.